Become a
SuperHealer™
By restoring the body’s capacity for organized tissue regeneration, Eluciderm aims to give people back what injury often takes away.
Eluciderm & The Return
to Generative Healing
Before Birth
Before birth, the body builds tissues through highly coordinated developmental programs. Wnt signaling guides vascularization, polarity, and structural organization, allowing skin and other tissues to form with flexibility, architecture, and functional integrity rather than scar.
Fibrotic Repair Dominates
Following Birth
Following birth, the body favors rapid wound closure, activating early canonical Wnt/β-catenin signaling that drives fibrotic repair. While effective for survival, this process often leaves behind scar tissue that compromises long-term tissue quality and function.
Insight
Eluciderm was founded on the observation that fibrosis and tissue repair may be distinct biological processes. By temporarily suppressing early scar-forming signals, generative modeling programs may become accessible during healing.
Restorative Reset™
Discovery
Eluciderm molecules modulate Poly(ADP-ribose) Polymerase (PARP) enzymes, influencing repair pathways that help determine whether tissue heals through fibrosis or more organized regeneration.
This shift in healing is designed to guide tissue repair away from fibrosis and toward the body’s natural capacity for organized tissue regeneration.
Platform
Eluciderm has developed a platform of small molecules that selectively modulate multiple Poly(ADP-ribose) polymerase (PARP) enzymes. PARP enzymes regulate DNA repair, cellular stress responses, immune signaling, inflammation, and tissue remodeling. By targeting different PARP enzymes and combinations of PARPs, the platform enables a growing portfolio of investigational therapeutics for applications including wound healing, regenerative medicine, aesthetics, fibrosis, immunology, and oncology.
PLATFORM OF SMALL MOLECULES
ELU42
Topical spray-on solution for open wound healing
ELU116
Topical investigational product for scar reduction and collagen enhancement
ELU507
Investigational inhalation product candidate for pulmonary fibrosis
ELU511
Topical investigational product for surgical and invasive procedure wound healing
ELU535
Topical investigational product for elastic cartilage regeneration
ELU569
ELU643
ELU700
NCI candidates for their potential as a treatment of leukemia and malignant melanoma
ELU42
ELU42 is Eluciderm’s lead therapeutic candidate and the first molecule developed from the company’s regenerative repair platform.
Winner
International Symposium for Advanced Wound Care (SAWC)
2024 WHS WoundShark Innovation Award
2026 Industrial R&D Award for Research on ELU42 Mechanism of Action
Skin Regeneration
Anywhere / Anytime
Unlike many wound treatments that have focused on oral, intravenous or injectable routes of administration, our patented lead therapeutic candidate ELU42 is formulated as a topical therapy, allowing treatment to be delivered directly to injured tissue while minimizing systemic exposure.
ELU42 Therapeutic Profile:
Regenerative Repair Signaling
Designed to locally modulate PARP-associated repair signaling, ELU42 has demonstrated clinical evidence of reduced fibrotic scarring while supporting angiogenesis, organized collagen remodeling, and regenerative healing.
Broad Clinical Potential
Direct application to wounds and traumatic injuries may enable use across surgical, hospital, wound care, and emergency settings.
Topical (Spray-On) Point-of-Care Delivery
As a topical therapy, ELU42 is designed for application at the site of injury, enabling early intervention when healing outcomes may be most influenced.
Operational Simplicity
Designed for spray-on administration, ELU42 may be stored under refrigerated or room-temperature conditions and applied without the need for a sterile environment, supporting use across diverse care settings.
Safety
Preclinical studies established a NOAEL (No Observed Adverse Effect Level), and Phase IIA clinical data support continued development as a topical therapeutic.
Eluciderm is a Clinical Stage Pharmaceutical Company
ELU42 is currently being evaluated in the SuperHealer Clinical Trial (Phase I/IIA: ELU42-01-01) for the treatment of diabetic foot ulcers. The trial is nearing completion, and internal safety and efficacy results remain encouraging, supported by robust preclinical proof of concept. ELU42 also received an R&D award at SAWC 2026 in recognition of its first in class regenerative mechanism. We are finalizing the complete clinical dataset for regulatory submission and plan to request a Type C/SPA meeting to help define the next stage of clinical development.
Patent Portfolio
Eluciderm’s patents for ELU42 provide protection through 2038, with pending filings that could extend exclusivity to 2047. Nine additional patents extend Eluciderm’s portfolio, covering more than 300 novel small-molecule analogs, strengthening the company’s long-term competitive moat.
